4D Molecular Therapeutics FDMT Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from 4D Molecular Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's debt-to-equity?
- 4D Molecular Therapeutics (FDMT) reported debt-to-equity of 0× in Q1 2026.
- How has 4D Molecular Therapeutics's debt-to-equity changed year-over-year?
- 4D Molecular Therapeutics's debt-to-equity decreased by 10.6% year-over-year, from 0.1× to 0×.
- What is the long-term trend for 4D Molecular Therapeutics's debt-to-equity?
- Over 5 years (2020 to 2025), 4D Molecular Therapeutics's debt-to-equity has grown at a -9.7% compound annual growth rate (CAGR), from 0.1× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.